COVID-19低氧性呼吸衰竭中无创机械通气与经鼻高流量氧疗、面罩及头盔的比较:一项随机对照试验
本研究为在阿曼三家三级中心进行的随机对照试验,纳入2021年2月4日至2021年8月9日期间PaO2/FiO2比值低于300的成人COVID-19患者,比较经鼻高流量氧疗(HFNC,n=47)、头盔持续气道正压(CPAP,n=52)和面罩CPAP(n=52)三种无创呼吸支持方式。159例随机化患者中151例纳入分析,中位年龄52岁,74%为男性。主要终点插管率在三组分别为44%、45%和46%(p=0.99),中位插管时间分别为7.0、5.5和4.5天(p=0.11);与面罩CPAP相比,HFNC和头盔CPAP的插管相对风险分别为0.97(95%CI 0.63-1.49)和1.0(95%CI 0.66-1.51)。28天死亡率分别为23%、32%和38%(p=0.24),90天死亡率分别为43%、38%和40%(p=0.89)。作者结论为三组插管率和死亡率无差异,但试验因病例减少提前终止,需更多证据确认。
要点
- 在COVID-19低氧性呼吸衰竭(PaO2/FiO2<300)成人患者中,HFNC、面罩CPAP和头盔CPAP三组的插管率分别为44%、45%和46%(p=0.99),无显著差异。
- 与面罩CPAP相比,HFNC的插管相对风险为0.97(95%CI 0.63-1.49),头盔CPAP为1.0(95%CI 0.66-1.51),置信区间均跨1。
- 三组28天死亡率分别为23%、32%和38%(p=0.24),90天死亡率分别为43%、38%和40%(p=0.89),均无显著差异。
- 中位插管时间在HFNC、面罩CPAP和头盔CPAP组分别为7.0、5.5和4.5天(p=0.11)。
- 作者认为该探索性试验三组插管率和死亡率无差异,但试验因病例减少提前终止,需更多证据确认这些发现。
适用人群与场景
- 成人COVID-19患者,PaO2/FiO2比值低于300,于2021年2月4日至2021年8月9日入住阿曼三家三级中心。
诊断标准与关键阈值
- 纳入标准:成人COVID-19患者,PaO2/FiO2比值低于300。
处置流程与药物剂量
- 干预措施包括经鼻高流量氧疗(HFNC,n=47)、头盔持续气道正压(CPAP,n=52)和面罩CPAP(n=52)。
研究设计与关键结果
- 研究类型为随机对照试验,采用区组随机化(每区组9例),平行、开放标签设计,在阿曼三家三级中心进行;共随机化159例,分析151例;中位年龄52岁,74%为男性。
- 主要终点插管率:HFNC组44%、面罩CPAP组45%、头盔CPAP组46%(p=0.99)。
- 中位插管时间:HFNC组7.0天、面罩CPAP组5.5天、头盔CPAP组4.5天(p=0.11)。
- 与面罩CPAP相比,插管的相对风险:HFNC为0.97(95%CI 0.63-1.49),头盔CPAP为1.0(95%CI 0.66-1.51)。
- 28天死亡率:HFNC组23%、面罩CPAP组32%、头盔CPAP组38%(p=0.24)。
- 90天死亡率:HFNC组43%、面罩CPAP组38%、头盔CPAP组40%(p=0.89)。
- 试验因病例减少提前终止。
证据类型、等级与局限
- 证据类型:随机对照试验(探索性)。
- 局限:试验因病例减少提前终止;作者结论指出需更多证据确认这些发现。
对床旁实践的改变
- 作者认为,对于COVID-19低氧性呼吸衰竭患者,HFNC、面罩CPAP和头盔CPAP三组在插管率和死亡率方面无差异。
- 作者指出,由于试验提前终止,需更多证据确认这些发现。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: For COVID-19-related respiratory failure, noninvasive respiratory assistance via a high-flow nasal cannula (HFNC), helmet, and face-mask noninvasive ventilation is used. However, which of these options is most effective is yet to be determined. This study aimed to compare the three techniques of noninvasive respiratory support and to determine the superior technique.
DESIGN: A randomized control trial with permuted block randomization of nine cases per block for each parallel, open-labeled arm.
SETTING AND PATIENTS: Adult patients with COVID-19 with a Pa o2 /F io2 ratio of less than 300, admitted between February 4, 2021, and August 9, 2021, to three tertiary centers in Oman, were studied.
INTERVENTIONS: This study included three interventions: HFNC ( n = 47), helmet continuous positive airway pressure (CPAP; n = 52), and face-mask CPAP ( n = 52).
MEASUREMENTS AND MAIN RESULTS: The endotracheal intubation rate and mortality at 28 and 90 days were measured as the primary and secondary outcomes, respectively. Of the 159 randomized patients, 151 were analyzed. The median age was 52 years, and 74% were men. The endotracheal intubation rates were 44%, 45%, and 46% ( p = 0.99), and the median intubation times were 7.0, 5.5, and 4.5 days ( p = 0.11) in the HFNC, face-mask CPAP, and helmet CPAP, respectively. In comparison to face-mask CPAP, the relative risk of intubation was 0.97 (95% CI, 0.63-1.49) for HFNC and 1.0 (95% CI 0.66-1.51) for helmet CPAP. The mortality rates were 23%, 32%, and 38% at 28 days ( p = 0.24) and 43%, 38%, and 40% ( p = 0.89) at 90 days for HFNC, face-mask CPAP, and helmet CPAP, respectively. The trial was stopped prematurely because of a decline in cases.
CONCLUSIONS: This exploratory trial found no difference in intubation rate and mortality among the three intervention groups for the COVID-19 patients with hypoxemic respiratory failure; however, more evidence is needed to confirm these findings as the trial was aborted prematurely.
参考来源
- Al Hashim AH, Al Reesi A, Al Lawati NM, et al. Comparison of Noninvasive Mechanical Ventilation With High-Flow Nasal Cannula, Face-Mask, and Helmet in Hypoxemic Respiratory Failure in Patients With COVID-19: A Randomized Controlled Trial. Crit Care Med. 2023. PMID: 37310174. doi:10.1097/CCM.0000000000005963
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。